Cardiology Now Has More than 200 FDA-Cleared AI Algorithms

Why It Matters

The surge in cleared cardiac AI expands diagnostic precision and workflow efficiency, enabling clinicians to detect disease earlier and streamline procedures. This momentum signals a broader shift toward AI‑driven care, attracting investment and reshaping the med‑tech landscape.

Key Takeaways

• Cardiology AI count exceeds 200 with imaging algorithms included
• FDA cleared 29 new cardiac AI tools in late 2025
• Radiology remains dominant with over 1,100 FDA‑cleared AI
• New AI spans ECG, echo, wearables, and procedural planning
• Annual FDA AI approvals approaching 200, accelerating adoption

Pulse Analysis

The FDA’s expanding clearance pipeline marks a watershed moment for artificial‑intelligence in medicine. With 1,451 clinical AI algorithms now authorized, the agency’s annual approvals are edging close to 200, a stark contrast to the single‑digit clearances of the 1990s. Radiology continues to dominate, boasting over 1,100 cleared tools, yet cardiology has surged past the 200‑algorithm threshold when cardiac‑specific imaging solutions are counted. This regulatory momentum underscores a broader industry confidence that AI can meet rigorous safety and efficacy standards. These clearances also provide a benchmark for future AI governance.

Cardiology’s AI arsenal now spans the entire diagnostic and therapeutic continuum. Algorithms such as HeartFlow Analysis and AngioWaveNet deliver real‑time physiological assessments from CT and angiography, while ECG‑focused platforms like DeepRhythmAI and Bunkerhill ECG‑EF automate arrhythmia detection and ejection‑fraction estimation. Wearable‑driven solutions, exemplified by Apple’s hypertension feature and Empatica’s remote monitoring, bring continuous data into the clinic. By automating image measurements, flagging high‑risk findings, and supporting procedural planning, these tools promise faster decision‑making, reduced inter‑observer variability, and potential cost savings. Clinicians report improved confidence when AI corroborates traditional readings.

The rapid influx of cleared AI products is reshaping investment patterns and competitive dynamics. Venture capital is gravitating toward firms that combine robust clinical validation with seamless integration into existing workflows, while established device manufacturers accelerate partnerships to embed AI into imaging hardware and point‑of‑care devices. Nevertheless, challenges remain: data privacy, algorithmic bias, and reimbursement pathways must be addressed to sustain growth. As the FDA’s clearance rate climbs, stakeholders that navigate regulatory, clinical, and commercial hurdles will capture the most value in the emerging AI‑centric cardiology market. Regulators are expected to refine post‑market surveillance to ensure long‑term safety.